Innovent and SanegeneBio Share Promising Phase 1 Data for IBI3016 at AHA 2025 Innovent and SanegeneBio unveil Phase 1 clinical data for IBI3016 at AHA 2025, showcasing its potential to treat hypertension effectively.

Innovent and SanegeneBio Share Promising Phase 1 Data for IBI3016 at AHA 2025 #China #Suzhou #Innovent #SanegeneBio #IBI3016